Cholesterol drug pelacarsen fails to prevent heart attacks in major trial

Summary

The experimental drug pelacarsen failed to reduce heart attacks, strokes, or cardiovascular deaths in a major trial of more than 8,000 patients, despite lowering dangerous lipoprotein(a) cholesterol by 78%. While cardiologists expressed shock at the outcome, they emphasize that testing for the genetic marker remains clinically valuable, and other investigational drugs targeting the protein remain in clinical development.

Key Takeaways

1. The failure of the Novartis drug pelacarsen to help people who have high levels of lipoprotein(a) stunned researchers, who called it a massive blow to preventive cardiology.
2. The drug did reduce Lp(a) significantly, by 78%, compared to a placebo drug that cut levels by 13%.
3. Experts stress that Lp(a) remains an important and valuable indicator of heart disease risk, even though the Horizon study failed to show any health benefit to driving down Lp(a) levels.

Statement Breakdown

• Claimed Facts: 70% of statements the article presents as facts
• Opinions: 30% of statements classified as editorial or subjective
• Claims: 0% of statements surfaced for additional reader evaluation

Credibility & Bias Reasoning

Credibility assessment: The article relies on findings presented at the American Heart Association meeting and published in the New England Journal of Medicine. It quotes the principal investigator of the clinical trial alongside multiple independent academic cardiologists. Key quantitative clinical trial figures and study details are provided directly from research results.

Bias assessment: Balanced Medical Reporting. The coverage presents a clinical trial failure in a neutral, informative tone without sensationalism. It features commentary from trial investigators, independent specialists, and guideline authors who describe both the disappointment of the result and its scientific context.

Note: Relies on clinical trial findings published in NEJM and comments from participating cardiologists.

Credibility flag: Trial Results

Claimed Facts (4)

• Reports the specific factual findings presented from the clinical trial data.
• States the objective enrollment parameters and participant count for the clinical study.
• Reports the official release and content of clinical practice recommendations.
• Reports the planned cessation of study on pelacarsen and the existence of competing developmental therapies.

Key Sources

• Dr. Steven Nissen — Chief academic officer of the Heart, Vascular & Thoracic Institute at Cleveland Clinic, study lead
• Dr. Amanda Doran — Assistant professor of medicine at Vanderbilt University Medical Center
• Dr. Karol Watson — Co-director of the UCLA Program in Preventive Cardiology
• Dr. John Wilkins — Cardiologist at Northwestern Medicine, guideline author
• American Heart Association — Cardiovascular medical society and conference host
• Erika Edwards — Health reporter for NBC News